FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma
Ipsen reported that the US FDA approved the Onivyde regimen (NALIRIFOX) as a first-line treatment for metastatic pancreatic cancer.
Ipsen reported that the US FDA approved the Onivyde regimen (NALIRIFOX) as a first-line treatment for metastatic pancreatic cancer.
What's Your Reaction?
